NEW YORK, Jan. 09, 2017 -- Evercel, Inc. (OTC:EVRC) today announced that it will hold its 2017 annual meeting of stockholders on Thursday, January 26, 2017 at 10:00 a.m. Eastern Time. The annual meeting will be held at the law offices of Ellenoff Grossman & Schole LLP at 1345 Avenue of the Americas, 11th Floor, New York, New York 10105. A formal notice of the annual meeting along with a proxy card has been sent to each of Evercel’s stockholders as of December 12, 2016. The formal notice includes instructions on how to vote at the annual meeting. Evercel encourages each stockholder to vote by proxy or attend the annual meeting in accordance with the instructions provided in the formal notice. Please refer to the website for more information on the proxy information at http://www.evercel.com/current-investor-information.
Contact: [email protected]


SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



